Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
US drugmaker Bristol Myers Squibb has announced three-year follow-up results from the Phase III CheckMate -816 trial. 30 March 2023
Biotechnology
The progress quietly made by Sino-American biotech company BeiGene with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable. 30 March 2023
Biotechnology
US biotech Scynexis’ shares were up more than 130% in pre-market trading after it revealed the signing of an exclusive licence agreement with UK pharma major GSK for Brexafemme (ibrexafungerp tablets). 30 March 2023
Biotechnology
Massachusetts, USA-based clinical-stage CNS biotech EIP Pharma has entered a definitive all-stock merger agreement with Diffusion Pharmaceuticals forming a publicly traded company, sending the latter’s share up 5% pre-market. 30 March 2023
Generics
The expiration of the patent for palbociclib, a leading anti-breast cancer drug, in India has opened up new opportunities for generic versions of the drug. The Indian government highlighted this development in Parliament and intensely discussed the endless possibilities that could arise from the availability of generic palbociclib and other similar generic oncology drugs, reports The Pharma Letter’s India correspondent. 30 March 2023
Biotechnology
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics revealed today that it has entered a collaboration agreement with Japan’s Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases. 30 March 2023
Biotechnology
The US Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase I/II VELA trial of BLU-222, said the drugs developer, Blueprint Medicines, sending the US biotech’s shares up 4% to $42.57. 30 March 2023
Pharmaceutical
US healthcare giant Johnson & Johnson has made the bold move of halting its investigational respiratory syncytial virus (RSV) adult vaccine program and discontinuing its Phase III EVERGREEN study. 30 March 2023
Biotechnology
Ireland-headquartered biotech Horizon Therapeutics today announced that the Italian medicines regulator, the AIFA, has approved the reimbursement of inebilizumab for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). 30 March 2023
Biotechnology
A short delay to bluebird bio’s US regulatory submission for lovo-cel (lovotibeglogene autotemcel) appears to have spooked investors, with shares in the company falling by a quarter. 30 March 2023
Biotechnology
New Jersey, USA-based cancer giant Merck has converted a conditional nod for its checkpoint blocker, Keytruda (pembrolizumab), into regular approval. 30 March 2023
Generics
After announcing the start of discussions early last year relating to its cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP), ViiV Healthcare, which is majority-owned by UK pharma major GSK, says an accord has now been struck with the Medicines Patent Pool (MPP). 30 March 2023
Biotechnology
US biotech firm Aridis Pharmaceuticals today revealed via a filing with the Securities and Exchange Commission (SEC) that it has received written notice from MedImmune, the global biologics R&D arm of Anglo-Swedish pharma major AstraZeneca, that it has terminated certain license agreement by and between MedImmune and the company dated as of July 12, 2021. 29 March 2023
Pharmaceutical
Théa Open Innovation (TOI) and Galimedix Therapeutics have announced the signing of a licensing agreement. 29 March 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year. 29 March 2023
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim reported a rise of 17% in its net sales for 2022 compared to the prior year. 29 March 2023
Biotechnology
The European Commission (EC) has approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression, US biotech firm Regeneron revealed today. 29 March 2023
Pharmaceutical
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
Biotechnology
Shares US biotech Bicycle Therapeutics closed up more than 11% at $22.40 yesterday, after it revealed a licensing deal that could earn it as much as $1.7 billion. 29 March 2023
Biotechnology
Results presented at the Society of Gynecologic Oncology (SGO) annual meeting have put two PD-1 inhibitors on course for a battle in the advanced endometrial cancer space. 29 March 2023
All news
Pharmaceutical
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
Biosimilars
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Pharmaceutical
Japanese drugmaker Otsuka has announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the manufacture and sale in Japan of bempedoic acid - trade name Nexletol in Japan - for the treatment of hypercholesterolemia and familial hypercholesterolemia. 27 November 2024
Pharmaceutical
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze